Interleukin 6 (Il 6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Interleukin-6 (IL-6) is a pleiotropic cytokine with critical roles in immune regulation, inflammation, and neuronal survival. IL-6 is implicated in the pathogenesis of multiple neurodegenerative diseases and is a target for therapeutic intervention[1]. In the central nervous system, IL-6 is produced by astrocytes, microglia, and neurons, and acts through the IL-6 receptor (IL-6R) and gp130 signal-transducing subunit[2].
IL-6 is a 21-28 kDa glycoprotein cytokine that signals through two distinct mechanisms:
Upon binding to IL-6R/gp130 complexes:
The balance between classical and trans-signaling determines the biological outcome, with trans-signaling often pro-inflammatory.
In the central nervous system, IL-6 is produced by various cell types:
IL-6 is elevated in the brains, CSF, and blood of Alzheimer's disease patients[3]:
The amyloid-beta-IL-6 axis represents a key pathway in AD pathogenesis, where amyloid plaques stimulate IL-6 production, which in turn enhances amyloid processing.
Elevated IL-6 is found in the substantia nigra, striatum, and CSF of PD patients[4]:
IL-6 polymorphisms have been associated with increased PD risk, suggesting a genetic component to IL-6-mediated neurodegeneration.
IL-6 has both detrimental and protective roles in cerebral ischemia[5]:
The timing of IL-6 modulation may determine whether its effects are beneficial or harmful.
Elevated IL-6 in CSF and serum correlates with progression in ALS patients[6]:
IL-6 promotes Th17 differentiation and demyelination in MS[7]:
Increased IL-6 is found in the striatum and cortex of HD patients:
Therapeutic strategies targeting IL-6 include:
Current research focuses on understanding the dual nature of IL-6 signaling in the CNS. Selective targeting of trans-signaling while preserving classical signaling represents a promising therapeutic approach. Biomarker studies are evaluating IL-6 levels for disease diagnosis and treatment response prediction.
Key research priorities include:
The study of Interleukin 6 (Il 6) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254-1266. DOI:10.7150/ijbs.5099
Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in neurological disorders. Acta Neuropathol Commun. 2016;4(1):123. DOI:10.1186/s40478-016-0376-5
Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68(10):930-941. DOI:10.1016/j.biopsych.2010.06.012
Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson's disease: a systematic review and meta-analysis. Front Immunol. 2016;7:274. DOI:10.3389/fimmu.2016.00274
Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. IL-6 in CNS autoimmunity. Adv Exp Med Biol. 2010;665:45-61. DOI:10.1007/978-1-4419-5912-3_4
Mitchell KM, Doty RL, Ilmarinen T, et al. IL-6 and disease progression in amyotrophic lateral sclerosis. Neurology. 2019;93(8):e746-e757. DOI:10.1212/WNL.0000000000007939
Korn T, Kallies A. IL-6 and its receptor in autoimmunity. Nat Rev Immunol. 2017;17(5):269-271. DOI:10.1038/nri.2017.22